2-phenoxyethyl acetoaceatate | 57582-44-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-phenoxyethyl acetoaceatate
• 英文别名: β-phenoxyethyl 3-oxo-butanoate；2-phenoxyethyl acetoacetate；Butanoic acid, 3-oxo-, 2-phenoxyethyl ester；2-phenoxyethyl 3-oxobutanoate
• CAS: 57582-44-2
• 化学式: C₁₂H₁₄O₄
• 分子量: 222.241
• InChiKey: OWKVONYXJNKQRG-UHFFFAOYSA-N

物化性质

• 沸点：
  318.2±17.0 °C(Predicted)
• 密度：
  1.130±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-phenoxyethyl acetoaceatate 在 哌啶 、 溶剂黄146 作用下， 以 叔丁醇 、 苯 为溶剂， 反应 48.0h， 生成 3-Cyclohexyl-1,6-dimethyl-4-(2-nitro-phenyl)-4,7-dihydro-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 2-phenoxy-ethyl ester; hydrochloride
  参考文献：
  名称：

  Studies on dihydropyridines. II. Synthesis of 4,7-dihydropyrazolo(3,4-b)pyridines with vasodilating and antihypertensive activities.

  摘要：

  合成了一系列4-芳基-4, 7-二氢吡唑[3, 4-b]吡啶-5-羧酸酯衍生物（72-149），并对这些化合物进行了在分离的豚鼠门静脉中的钙通道阻滞活性、自发性高血压大鼠中的抗高血压活性以及在分离的豚鼠心脏中的冠状血管扩张作用的测试。多种衍生物具有强效的抗高血压和冠状血管扩张活性。该系列的结构-活性关系表明，3-环戊基或3-环己基取代基以及具有适度体积的疏水性5-酯基团对于提高药理活性是有效的。

  DOI：

  10.1248/cpb.35.3235
• 作为产物：
  描述：

  双乙烯酮 、 己二酸,聚合2,2-二甲基-1,3-丙二醇和2,5-呋喃二酮,苯酸酯 反应 22.0h， 以to obtain 90.6 g of 2-phenoxyethyl acetoacetate, BP 140°-145° C./0.3 mm的产率得到2-phenoxyethyl acetoaceatate
  参考文献：
  名称：

  1,4,5,6,7,8-Hexahydro-2-alkyl-4-aryl-5-oxo-1,7-naphthyridine-3-carboxyl

  摘要：

  1,4,5,6,7,8-六氢-2-烷基-4-芳基-5-氧代-1,7-萘啶-3-羧酸芳香酯及其药学上可接受的酸盐是有用的降压药剂。

  公开号：

  US04596873A1

文献信息

• 6-Acyloryalkyl-1,4-dihydropyridine derivatives and a method of effecting
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04145432A1

  公开（公告）日：1979-03-20

  This invention relates to 1,4-dihydropyridine derivatives. More particularly, it relates to new 1,4-dihydropyridine derivatives thereof which have vasodilating and anti-hypertensive activity, to processes for the preparation thereof, and to pharmaceutical composition comprising the same for therapeutical treatment in cardiovascular diseases and hypertension in human being.

  这项发明涉及1,4-二氢吡啶衍生物。更具体地，它涉及具有扩血管和降压活性的新1,4-二氢吡啶衍生物，以及其制备方法，以及包含相同的用于治疗人类心血管疾病和高血压的药物组合物。
• 1,4-Dihydropyridine derivatives, and pharmaceutical method of the same
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04284634A1

  公开（公告）日：1981-08-18

  1,4-dihydropyridine derivatives of the general formula ##STR1## having vasodilating and anti-hypertensive activity, processes for preparing same, and pharmaceutical compositions thereof for treating cardiovascular diseases.

  一般式为##STR1##的1,4-二氢吡啶衍生物具有扩血管和降压活性，制备方法以及用于治疗心血管疾病的药物组合物。
• Soil fungi inhibiting agent
  申请人：Nissan Chemical Industries, Ltd.

  公开号：US04036984A1

  公开（公告）日：1977-07-19

  Soil fungi-inhibiting agent containing as the active ingredient one or more of the compounds represented by the following general formula ##STR1## wherein I. WHEN BOTH X and Y are oxygen atoms, Z is hydrogen atom, unsubstituted alkyl group, unsubstituted alkenyl group, ##STR2## (in this case the compound is p-toluene sulfonate), NH.sub.2 CH.sub.2 -- (in this case the compound is p-toluene sulfonate), acyl group, ClCH.sub.2 CONH--, or alkyl group substituted by substituents such as R.sub.1 COO--, CH.sub.3 COS--, R.sub.2 O--, R.sub.2 S--, HO--, HOOC--, CH.sub.3 CONH--, acyl group, alkoxyacyl group, where R.sub.1 is lower-alkyl group or alkenyl group, R.sub.2 is lower-alkyl group or benzyl group; Ii. when X is oxygen and Y is sulfur or --NH--, Z is lower alkyl group; Iii. when X is sulfur and Y is oxygen, Z is lower-alkyl group, acetylmethyl group, methoxymethyl group, 2-methyl-1-propynyl group or nitromethyl group; Iv. when X is sulfur and Y is --NH--, Z is lower-alkyl group.

  土壤真菌抑制剂，其活性成分为下列通式所示的一个或多个化合物：其中I. 当X和Y均为氧原子时，Z为氢原子、未取代的烷基基团、未取代的烯基基团、(在这种情况下，化合物为对甲苯磺酸盐)、NH.sub.2 CH.sub.2 -- (在这种情况下，化合物为对甲苯磺酸盐)、酰基基团、ClCH.sub.2 CONH--，或者被R.sub.1 COO--、CH.sub.3 COS--、R.sub.2 O--、R.sub.2 S--、HO--、HOOC--、CH.sub.3 CONH--等取代基取代的烷基基团、醚酰基团，其中R.sub.1为低烷基基团或烯基基团，R.sub.2为低烷基基团或苄基；II. 当X为氧，Y为硫或--NH--时，Z为低烷基基团；III. 当X为硫，Y为氧时，Z为低烷基基团、乙酰甲基基团、甲氧基甲基基团、2-甲基-1-丙炔基团或硝基甲基基团；IV. 当X为硫，Y为--NH--时，Z为低烷基基团。
• Studies on Nilvadipine. II. Synthesis and Structure-Activity Relationships of 2-Hydroxymethyl- and 2-Cyano-1,4-dihydropyridines Containing Heteroatom-Substituted Ester at the 5-Position.
  作者：Yoshinari SATOH、Masaharu ICHIHASHI、Kazuo OKUMURA

  DOI：10.1248/cpb.40.912

  日期：——

  The synthesis of new 2-hydroxymethyl- and 2-cyano-1, 4-dihydropyridines possessing a heteroatom-substituted alkyl ester group at the 5-position of the nucleus in described. The esters were introduced via a suitable method selected from the modified Hantzsch method (method A), the hydrolysis of a chloroethyl ester obtained by method A (method B) or the replacement of the chlorine atom with various kinds of amino groups (method C). Hydroxymethyl and cyano groups at the 2-position were prepared in a similar manner to that described in a previous papare.1)The hypotensive activities of the compounds prepared in this paper were compared with the corresponding alkyl ester at the 5-position reported previously. It was found that N-benzylmethylaminoethyl esters, especially N-(4-chlorobenzyl)-and N-(3, 4-dichlorobenzyl)-N-methylaminoethyl esters, were suitable substituents at the 5-position of the 1, 4-dihydropyridine nucleus and that these substituents were somewhat more effective for hypotensive activity than simple alkyl esters in a series of 2-hydroxymethyl-1, 4-dihydropyridine derivatives. But it was found that the effect was reversed in a series of 2-cyano-1, 4-dihydropyridine derivatives. Both of them were found to be inferior to nilvadipine (1c), accepted in clinical use for the treatment of hypertension.

  描述了新型2-羟甲基-和2-氰基-1, 4-二氢吡啶的合成，这些化合物在其核的5位上具有杂原子取代的烷基酯基团。酯的引入是通过以下方法之一进行的：经过改进的Hantzsch方法（方法A）、通过方法A获得的氯乙酸酯的水解（方法B）或用各种氨基取代氯原子（方法C）。2位的羟甲基和氰基团的制备与之前的文献相似。1）本文中制备的化合物的降压活性与之前报告的在5位的相应烷基酯进行了比较。发现N-苄基甲基氨基乙酯，特别是N-(4-氯苄基)-和N-(3, 4-二氯苄基)-N-甲基氨基乙酯，是1, 4-二氢吡啶核5位上合适的取代基，并且在一系列2-羟甲基-1, 4-二氢吡啶衍生物中，这些取代基的降压活性比简单的烷基酯略强。然而，在一系列2-氰基-1, 4-二氢吡啶衍生物中，效果则相反。两者均被发现不如已经在临床上用于治疗高血压的nilvadipine (1c)。
• Certain 4-aryl-1,4-dihydro-3,5-pyridinedicarboxylates having
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04525478A1

  公开（公告）日：1985-06-25

  1,4-Dihydropyridine derivatives of the general formula ##STR1## having vasodilating and anti-hypertensive activity, processes for preparing same, and pharmaceutical compositions thereof for treating cardiovascular diseases.

  具有扩血管和降压活性的一般式为##STR1##的1,4-二氢吡啶衍生物，其制备方法以及用于治疗心血管疾病的制药组合物。